Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

44.39 0.25 +0.57%
Market cap
$64.0B
P/E
17.9×
Fwd P/E
17.8×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

12.52% 12.47% 14.69% 15.37%
Piotroski F-Score
6 7 8 7
ROA
6.91% 6.98% 8.44% 8.47%
ROIC
6.38% 6.65% 6.64% 6.96%
Return on Tangible Assets
42.94% 39.21% 43.60% 64.81%
Average Days of Receivables
53.34 53.20 53.60 53.01
Free Cash Flow per Share
2.58 2.47 2.34 2.47
Free Cash Flow
3,824.00 3,658.00 3,475.00 3,625.00
Other line items

Show all line items

Columns are period end dates